SAN FRANCISCO--(BUSINESS WIRE)--April 24, 2006--NeoPharm, Inc. (Nasdaq: NEOL - News): Median Survival Of More Than One Year Observed Catheter Placement Key Predictor of Prolonged Survival NeoPharm, Inc. (Nasdaq:NEOL - News) today announced that cintredekin besudotox (IL13-PE38QQR) continues to show evidence of prolonged overall survival in patients with recurrent glioblastoma multiforme (GBM). Updated data for GBM patients treated in Phase I/II studies and results from a Phase I/II subset analysis is being presented at the 74th Annual Meeting of the American Association of Neurological Surgeons (AANS) held in San Francisco on Monday, April 24, 2006.
